BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2011
View Archived Issues
Monash University develops dual-action PILs for fast delivery of active pharmaceutical ingredients
Read More
New hepcidin inhibitor exhibits antianemic effects in vivo
Read More
Phase II ARRY-520 trial in multiple myeloma yields encouraging results
Read More
Phase I study evaluates SCH-900776/cytarabine combination for leukemia
Read More
Oral rigosertib shows promise as a therapy for myelodysplastic syndrome
Read More
Asahi Kasei integrates two core operating companies
Read More
Celldex completes accrual in CDX-011 study
Read More
Astellas Pharma and UMN Pharma report phase I/II data on seasonal flu vaccine
Read More
Merck & Co. patents new hPDK1 inhibitors
Read More
Novel farnesyl pyrophosphate synthase inhibitors discovered in Canada
Read More
Janssen Pharmaceutica discloses novel estrogen-related receptor-alpha ligands
Read More
Enrollment begins in phase III trial of CF-101
Read More
NIAID begins trial of experimental chikungunya fever vaccine
Read More
Exelixis grants program license to Merck & Co.
Read More
Belgium-based company first to advance fatty acid FFA2 receptor antagonist to clinic
Read More
Novel fused imidazole derivatives prepared by Toa Eiyo
Read More
Abbott synthesizes new voltage-gated Ca(V)2.2 calcium channel antagonists
Read More
First patient with metastasized colorectal cancer treated in phase II trial of armed oncolytic virus
Read More
Phage Pharmaceuticals submits IND for first-in-class therapeutic
Read More
CytRx launches phase IIb study in advanced soft tissue sarcoma
Read More
Chelsea Therapeutics announces new data on droxidopa in fibromyalgia
Read More
Valeant Pharmaceuticals completes acquisition
Read More
Santarus files NDA for budesonide tablets
Read More
Trial of new patch for osteoporosis meets endpoints
Read More
XOMA commences new study of gevokizumab
Read More
MorphoSys commences clinical testing of MOR-103 for new indication
Read More